---
title: Eli Lilly Zepbound Weight Loss Drug, Now FDA Approved
excerpt: The Eli Lilly drug known as Zepbound, previously Wegovy, is now an approved FDA drug for weight loss.
---
![Zepbound product image - front](https://images.ctfassets.net/srys4ukjcerm/5oGWoiHa7RhVLKBE2akl3f/112fa1ea9589f21a627a303f6102e5b7/ZepBoundV2_DeviceFront_2pt5.png)

The Eli Lilly drug known as Zepbound, previously Wegovy, is now an approved FDA drug for weight loss. 

The  [Eli Lilly Investor Release](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight) (Nov 8, 2023) states that when taken in conjunction with exercise and a healthy diet, people taking [Zepbound](/weight-loss/drugs//eli-lilly-zepbound-weight-loss-drug) lost an average of around 40 lbs. 

Zepbound also notes on their label that gastrointestinal side effects were more common among those taking the drug as compared to those on placebo. 

They advise against use for people diagnosed, or have a family history with:
- medullar thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- hypersensitivity to terzapatide

Expected to become available in the U.S. by the end of the year in size doses (2.4 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg)